SLC1A4

Across TCGA pan-cancer cohorts, SLC1A4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC1A4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC1A4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC1A4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where SLC1A4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	21	view →
HNSC	OS	Median	All	1.000	0.377	.022	13	view →
GBM	OS	Median	All	0.499	0.274	.016	6	view →
CCRCC	DFS	Median	IV	0.233	1.000	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC1A4–PDAC (DFS)

Open the PDAC breakdown →